Genmab A/S Price Chart
Genmab A/S GE9.F Financial and Trading Overview
| Genmab A/S stock price | 279 EUR |
| Previous Close | 353.1 EUR |
| Open | 353 EUR |
| Bid | 361.2 EUR x 20000 |
| Ask | 362.3 EUR x 20000 |
| Day's Range | 353 - 353 EUR |
| 52 Week Range | 257.1 - 445.1 EUR |
| Volume | 6 EUR |
| Avg. Volume | 31 EUR |
| Market Cap | 21.81B EUR |
| Beta (5Y Monthly) | 0.683524 |
| PE Ratio (TTM) | 72.64869 |
| EPS (TTM) | 4.86 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 480.81 EUR |
GE9.F Valuation Measures
| Enterprise Value | -508828800 EUR |
| Trailing P/E | 72.64869 |
| Forward P/E | 45.431145 |
| PEG Ratio (5 yr expected) | 204.55 |
| Price/Sales (ttm) | 1.4227788 |
| Price/Book (mrq) | 0.8467644 |
| Enterprise Value/Revenue | -0.033 |
| Enterprise Value/EBITDA | -0.076 |
Trading Information
Genmab A/S Stock Price History
| Beta (5Y Monthly) | 0.683524 |
| 52-Week Change | 35.16% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 445.1 EUR |
| 52 Week Low | 257.1 EUR |
| 50-Day Moving Average | 365.51 EUR |
| 200-Day Moving Average | 369.9 EUR |
GE9.F Share Statistics
| Avg. Volume (3 month) | 31 EUR |
| Avg. Daily Volume (10-Days) | 19 EUR |
| Shares Outstanding | 61.49M |
| Float | 64.42M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 49.71% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 34.46% |
| Operating Margin (ttm) | 41.21% |
| Gross Margin | 100.00% |
| EBITDA Margin | 43.45% |
Management Effectiveness
| Return on Assets (ttm) | 14.27% |
| Return on Equity (ttm) | 21.17% |
Income Statement
| Revenue (ttm) | 15.33B EUR |
| Revenue Per Share (ttm) | 234.61 EUR |
| Quarterly Revenue Growth (yoy) | 34.69% |
| Gross Profit (ttm) | 14.6B EUR |
| EBITDA | 6.66B EUR |
| Net Income Avi to Common (ttm) | 5.28B EUR |
| Diluted EPS (ttm) | 4.859 |
| Quarterly Earnings Growth (yoy) | -51.39% |
Balance Sheet
| Total Cash (mrq) | 24.54B EUR |
| Total Cash Per Share (mrq) | 376.31 EUR |
| Total Debt (mrq) | 829M EUR |
| Total Debt/Equity (mrq) | 3.05 EUR |
| Current Ratio (mrq) | 14.44 |
| Book Value Per Share (mrq) | 416.881 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 6.56B EUR |
| Levered Free Cash Flow (ttm) | 4.53B EUR |
Profile of Genmab A/S
| Country | Germany |
| State | N/A |
| City | Copenhagen |
| Address | Kalvebod Brygge 43 |
| ZIP | 1560 |
| Phone | 45 70 20 27 28 |
| Website | https://www.genmab.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 1846 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Q&A For Genmab A/S Stock
What is a current GE9.F stock price?
Genmab A/S GE9.F stock price today per share is 279 EUR.
How to purchase Genmab A/S stock?
You can buy GE9.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genmab A/S?
The stock symbol or ticker of Genmab A/S is GE9.F.
How many shares does Genmab A/S have in circulation?
The max supply of Genmab A/S shares is 61.79M.
What is Genmab A/S Price to Earnings Ratio (PE Ratio)?
Genmab A/S PE Ratio is 57.41922000 now.
What was Genmab A/S earnings per share over the trailing 12 months (TTM)?
Genmab A/S EPS is 4.86 EUR over the trailing 12 months.